![Tumor Marker:- Part 4 - CA-Antigens, CA 15-3, CA 549, CA 27.29, CA 125, CA 19-9, CA 72-4 - Labpedia.net Tumor Marker:- Part 4 - CA-Antigens, CA 15-3, CA 549, CA 27.29, CA 125, CA 19-9, CA 72-4 - Labpedia.net](https://labpedia.net/wp-content/uploads/2020/01/Tumor-marker-diagnosis-prognosis-3-1024x807.jpg)
Tumor Marker:- Part 4 - CA-Antigens, CA 15-3, CA 549, CA 27.29, CA 125, CA 19-9, CA 72-4 - Labpedia.net
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1292-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9a3953cd-13fb-4c8c-9302-3b71a84b2e23/gr1_lrg.jpg)
How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - Digestive and Liver Disease
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1288-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1413867015001944:gr2.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/qSCRz5Ib+l7k+w1jVIYLy+x9hT2kumM6W8qgi/U+qBd+ZSkUVK08WrCDiDbtm65hxkhZgGpPQisVcmJ0bBAPSPJ2ulzFXXEVU664x8w0rUdsCt8+ziC4W6uwiWGgy5aRsctuEgkMfMpDPPPfXhpSFn4PLd/p8Mn0Xqkk3GZUx2e8tYOBbaLrQw2o8CAxQJxTD2uJp6rFIgsXR+EoSkcjNPWyYBqe4ZZYLnB94b8HFaidTDDrm+IoHxVey9ptGXBbtUYGP1cW38DF10I67YRMw=)
Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases
![Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing](https://www.aclr.com.es/articles-images/annals-clinical-four-tumor-marker-3-3-32-g001.png)
Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1293-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig1_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Table 2 from Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis | Semantic Scholar Table 2 from Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9cbea13732ed9f9299e409d9fb7b272385d2ae69/4-Table2-1.png)
Table 2 from Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis | Semantic Scholar
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig3_HTML.png)